Forty Years of Publication of Transplantation Proceedings-The Second Decade: The Cyclosporine Revolution

Transplantation Proceedings

Volumn 41, Issue 5, 2009, Pages 1423-1437

  Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ENISOPROST; GANCICLOVIR; LYMPHOCYTE ANTIBODY; MISOPROSTOL; MIZORIBINE; OKT 3; PREDNISONE; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIBODY DETECTION; ARTICLE; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOBIOLOGY; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LOW DRUG DOSE; LYMPH NODE IRRADIATION; MEDICAL ETHICS; MYOCARDITIS; NEPHROTOXICITY; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PREOPERATIVE CARE; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE TYPING; VIRUS PNEUMONIA;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; GRAFT REJECTION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; KIDNEY; PERIODICALS AS TOPIC; TACROLIMUS; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 67249090040     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.05.001     Document Type: Article

References (329)

1. Starzl T.E., Koep L.J., Halgrimson C.G., et al. Liver transplantation-1978. Transplant Proc 11 (1979) 240
2. Griepp R.B. A decade of human heart transplantation. Transplant Proc 11 (1979) 285
3. Santos G.W., Elfenbein G.J., and Tutschka P.J. Bone marrow transplantation-present status. Transplant Proc 11 (1979) 182
4. Najarian J.S., Sutherland D.E., Matas A.J., et al. Human islet autotransplantation following pancreatectomy. Transplant Proc 11 (1979) 336
5. Sutherland D.E., and Najarian J.S. Transplantation of the pancreas. Transplant Proc 11 (1979) 1158
6. Dubernard J.M., Traeger J., and Neyra P. Long-term effect of néoprène injection in the canine pancreatic duct. Transplant Proc 11 (1979) 1498
7. Valente U., Ferro M., Campisi C., et al. Allogeneic pancreatic islet transplantation by means of artificial membranechambers in 13 diabetic recipients. Transplant Proc 12 Suppl 2 (1980) 223
8. Groth C.G., Anderson A., Björkén C., et al. Attempts at transplantation of fetal pancreas to diabetic patients. Transplant Proc 12 Suppl 2 (1980) 208
9. Starzl T.E., Koep U., Weil III R., et al. Thoracic duct drainage in organ transplantation: Will it permit better immunosuppression?. Transplant Proc 11 (1979) 276
10. Strober S., Gottlieb M., Slavin S., Hoppe R., Grumet F.C., and Kaplan H.S. Use of total lymphoid irradiation (TLI) in bone marrow and organ transplantation. Transplant Proc 11 (1979) 1930
11. Strober S., Gottlieb M., Slavin S., et al. Immunosuppression and tolerance after total lymphoid irradiation (TLI). Transplant Proc 12 (1980) 477
12. Calne R.Y., White D.J., Pentlow B.D., et al. Cyclosporin A: preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc 11 (1979) 860
13. Richie R.E., Niblack G., Johnson H.K., and Tallent M.B. Thoracic duct drainage in transplantation. Transplant Proc 12 (1980) 483
14. Fish J.C., Sarles H.E., Remmers Jr. A.R., et al. Renal transplantation after thoracic duct drainage. Transplant Proc 13 (1981) 531
15. Rapaport F.T., Bachvaroff R.J., Akiyama N., and Sato T. Induction of allogeneic unresponsiveness by supralethal irradiation and bone marrow reconstitution. Transplant Proc 12 (1980) 473
16. Strober S., King D.P., Gottlieb M.S., et al. Cellular mechanisms of tolerance after total lymphoid irradiation (TLI). Transplant Proc 13 (1981) 556
17. Schwadron R.B., and Strober S. Cloned natural suppressor cells derived from the neonatal spleen: in vitro action and lineage. Transplant Proc 19 (1987) 533
18. Vanrenterghem Y., Waer M., Roels L., and Michielsen P. A controlled trial comparing pretransplant total lymphoid irradiation versus posttransplant cyclosporine in type 1 diabetic cadaveric kidney graft recipients: short-term results. Transplant Proc 19 (1987) 1542 Feb;19(1 Pt 2):1542-3
19. Cooper D.K., Human P.A., and Reichart B. Prolongation of cardiac xenograft (vervet monkey to baboon) function by a combination of total lymphoid irradiation and immunosuppressive drug therapy. Transplant Proc 19 (1987) 4441
20. Myburgh J.A., Meyers A.M., Botha J.R., et al. Wide field low-dose total lymphoid irradiation in clinical kidney transplantation. Transplant Proc 19 (1987) 1974
21. Myburgh J.A., and Smit J.A. Autoantiidiotypic immunization and transplantation tolerance in the primate. Transplant Proc 11 (1979) 923
22. White D.J., Calne R.Y., and Plumb A. Mode of action of cyclosporine A: a new immunosuppressive agent. Transplant Proc 11 (1979) 855
23. Fernando O.N., Sweny P., Farrington K., Rogers H., Baillod R.A., Chan M.K., Varghese Z., and Moorhead J.F. Preliminary experience with cyclosporine A in human renal allografts. Transplant Proc 12 2 (1980 Jun) 244-245
24. Dunn D.C., White D.J., Herbertson B.M., and Rolles K. Detrimental effect of steroids on cyclosporin-A-induced prolonged allograft survival. Transplant Proc Jun 12 (1980) 335
25. Thiel G., Harder F., Loerscher R., Brünisholz M., et al. Cyclosporine alone or in combination with prednisone in cadaveric renal transplantation. Transplant Proc 16 (1984) 1187
26. Beveridge T. Cyclosporin-A: an evaluation of clinical results. Trans Proc 15 (1983) 433
27. Kahan B.D. The First International Congress on Cyclosporine. May 16-19, 1983, Houston, Texas. Transplant Proc 15 Suppl 1-2 (1983) 2207
28. Stiller C., and London Canada for the Canadian Transplant Study Group. The Canadian trial of cyclosporine: cyclosporine therapy compared to standard immunosuppression in renal transplants: an exploration of nephrotoxicity. Transplant Proc 15 Suppl 1-2 (1983) 2479
29. Canafax D.M., Simmons R.L., Sutherland D.E., et al. Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporine versus antilymphocyte globulin-azathioprine. Transplant Proc 18 Suppl 1 (1986) 192
30. Najarian J.S., Strand M., Fryd D.S., et al. Comparison of cyclosporine versus Azathioprine-antilymphocyte globulin in renal transplantation. Transplant Proc 15 Suppl 1-2 (1983) 2463
31. Starzl T.E., Hakala T.R., Rosenthal J.T., et al. The Colorado-Pittsburgh cadaveric renal transplantation study with cyclosporine. Transplant Proc 15 Suppl 1-2 (1983) 2459
32. Kahan B.D., Van Buren C.T., and Flechner S.M. Cyclosporine Immunosuppression mitigates immunologic risk factors in renal allotransplantation. Transplant Proc 15 Suppl 1-2 (1983) 2469
33. Land W. Cyclosporine in cadaveric renal transplantation: five-year follow-up results of the European Multicentre Trial. Transplant Proc 20 Suppl 3 (1985) 73
34. Margreiter R., Lang A., Koenig P., et al. Cyclosporine in the treatment of acute allograft rejection refractory to high-dose methylprednisolone: results of a prospectively randomized trial. Transplant Proc 16 (1984) 1202
35. Evans R.W., and Manninen D.L. Economic impact of cyclosporine in transplantation. Transplant Proc 20 Suppl 3 (1988) 49
36. Didlake R.H., Dreyfus K., and Kerman R.H. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 20 Suppl 3 (1988) 63
37. Iwatsuki S., Van Thiel D.H., Gartner J.C., et al. Report of Colorado-Pittsburgh liver transplantation studies. Transplant Proc 15 Suppl 1-2 (1983) 2582
38. Oyer P.E., Stinson E.B., Jamieson S.W., et al. Cyclosporine in cadaveric transplantation: A 21/2 year follow-up. Transplant Proc 15 Suppl 1-2 (1983) 2446
39. Cooley D.A., Frazier O.H., Painvin G.A., et al. Cardiac and Cardiopulmonary transplantation using cyclosporine for Immunosuppression: recent Texas Heart Institute experience. Transplant Proc 15 Suppl 1-2 (1983) 2567
40. Hardesty R.L., Griffith B.P., Debski R.F., et al. Experience with cyclosporine in cardiac transplantation. Transplant Proc 15 Suppl 1-2 (1983) 2553
41. Wallwork J., Cory-Pearce R., and English T.A.H. Cyclosporine for cardiac transplantation: U.K. Trial Transplant Proc 15 Suppl 1-2 (1983) 2606
42. Powles R.L., Evans B., Poole C., et al. Cyclosporine for the prevention of graft-vs-host disease in 72 patients with acute myeloblastic leukemia in first remission receiving matched sibling bone marrow transplants. Transplant Proc 15 Suppl 1-2 (1983) 2624
43. Gluckman E., Devergie A., Poirier O., and Lokiec F. Use of cyclosporine as prophylaxis of graft-vs-host disease after human allogeneic bone marrow transplantation: report of 38 patients. Transplant Proc 15 Suppl 1-2 (1983) 2628
44. Storb R., Deeg H.J., Thomas E.D., et al. Preliminary results of prospective randomized trials comparing methotrexate and cyclosporine for prophylaxis of graft-vs-host-disease after HLA-identical marrow transplantations. Transplant Proc 15 Suppl 1-2 (1983) 2628
45. Sutherland D.E.R., Chinn P.L., Goetz F.C., et al. Experience with cyclosporine versus Azathioprine for pancreas transplantation. Transplant Proc 15 Suppl 1-2 (1983) 2559
46. Van Schilfgaarde R., Persijn G.G., and Sutherland D.E.R. First International Symposium on Organ Transplantation in Diabetics. The Hague, 1-2 September 1983. Transplant Proc 16 (1984) 565
47. McMaster P., Michael J., Adu D., et al. Combined kidney and pancreas grafting-is it really safe and does it jeopardize the kidney?. Transplant Proc 16 (1984) 704
48. Landgraf R., Landgraf-Leurs M.M., Burg D., et al. Follow-up of simultaneous kidney and pancreas transplantation in type I diabetes. Transplant Proc 16 (1984) 687
49. First M.R., Munda R., Kant K.S., et al. Steroid withdrawal following HLA-identical related donor transplantation. Transplant Proc 13 (1981) 319
50. Steinman T.I., Zimmerman C.E., Monaco A.P., et al. Steroids can be stopped in kidney transplant recipients. Transplant Proc 13 (1981) 323
51. Lloveras J., Masramon J., Orfila A., et al. Stopping prednisone in kidney transplant recipients taking cyclosporine: safety conditions. Transplant Proc 19 (1987) 2027
52. Salaman J. Cyclosporine mono-drug therapy. Transplant Proc 20 Suppl 3 (1988) 117
53. Birkeland S.A., Foged N., Kold A.A., et al. Conversion of long-term renal allograft recipients from prednisolone/azathioprine to cyclosporine monotherapy. Transplant Proc 20 Suppl 3 (1988) 171
54. MacDonald A.S., Daloze P., Dandavino R., et al. A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Canadian Transplant Group. Transplant Proc 19 Pt 3 (1987) 1865
55. Hourmant M., Buzelin F., Dubigeon P., et al. High long-term graft survival rates in kidney transplantation with the sequential association of antithymocyte globulin and cyclosporine A monotherapy. Transplant Proc 19 Pt 3 (1987) 2113
56. Lennard T.W., Venning M., Donnelly P.K., et al. Conversion of immunosuppression in renal allograft recipients from cyclosporine A to azathioprine and prednisolone 6 months after transplantation. Transplant Proc 19 (1987) 3594
57. Zehnder C., Beveridge T., Nüesch E., et al. Cyclosporine A capsules: bioavailability and clinical acceptance study in renal transplant patients. Transplant Proc 20 Suppl 2 (1988) 641
58. Black K.S., Hewitt C.W., Chau C.L., and Pizzo L. Transdermal application of cyclosporine prolongs skin allograft survival. Transplant Proc 20 Suppl 2 (1988) 660
59. BenEzra D., Matamoros N., and Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc 20 Suppl 2 (1988) 644
60. Wenger R. Cyclosporine and analogues: structural requirements for immunosuppressive activity. Transplant Proc 18 Suppl 5 (1986) 213
61. Ryffel B., Hiestand P., Foxwell B., et al. Nephrotoxic and immunosuppressive potentials of cyclosporine metabolites in rats. Transplant Proc 18 Suppl 5 (1986) 41
62. Schlitt H.J., Christians U., Wonigeit K., et al. Immunosuppressive activity of cyclosporine metabolites in vitro. Transplant Proc 19 (1987) 4248
63. Grant D., Freeman D., Keown P., et al. Pharmacokinetic and pharmacodynamic profiles of cyclosporine and cyclosporine G in dogs. Transplant Proc 19 (1987) 3494
64. Borel J.F. Immunosuppressive properties of cyclosporin A (CY-A). Transplant Proc 12 (1980) 233
65. Garvey J.F., McShane P., Poole M.D., et al. The effect of cyclosporine A on experimental pancreas allografts in the rat. Transplant Proc 12 (1980) 266
66. Rynasiewicz J.J., Sutherland D.E., Kawahara K., et al. Cyclosporine A prolongation of segmental pancreatic and islet allograft function in rats. Transplant Proc 12 (1980) 270
67. McMaster P., Procyshyn A., Calne R.Y., et al. Prolongation of canine pancreas allografts with cyclosporin A. Transplant Proc 12 (1980) 275
68. Simms M.H., Cruickshank J.K., Blainey J.D., et al. Effects of cyclosporin A in rat kidney grafts. Transplant Proc 12 (1980) 256
69. van Bekkum D.W., Knaan S., and Zurcher C. Effects of cyclosporin A on experimental graft- versus host disease in rodents. Transplant Proc 12 (1980) 278
70. White D.J., Rolles K., Ottawa T., and Turell O. Cyclosporin-A-induced long-term survival of fully incompatible skin and heart grafts in rats. Transplant Proc 12 (1980) 261
71. Drugge R.J., and Handschumacher R.E. Cyclosporine-mechanism of action. Transplant Proc 20 Suppl 2 (1988) 301
72. Hess A.D., and Colombani P.M. Mechanism of actions of cyclosporine: role of calmodulin, cyclophilin, and other cyclosporine-binding proteins. Transplant Proc 18 Suppl 5 (1986) 219
73. Schleuning M., Duggan A., and Reem G.H. Cyclosporine does not inhibit the early transducing signals generated by the activation of human thymocytes. Transplant Proc 20 Suppl 2 (1988) 63
74. Citterio F., and Kahan B.D. Effects of cyclosporine on nuclear function. Transplant Proc 20 Suppl 2 (1988) 75
75. Yoshimura N., Kahan B.D., Matsui S., et al. Cyclosporine effect on immunoregulatory cells in kidney transplant recipients: suppression of gamma-interferon and interleukin production. Transplant Proc 20 Suppl 2 (1988) 69
76. Bloemena E., van Oers M.H., Weinreich S., et al. Cyclosporine A does not prevent expression of biologically active IL 2 receptors in vitro. Transplant Proc 20 Suppl 2 (1988) 131
77. Kupiec-Weglinski J.W., Hahn H.J., Kirkman R.L., et al. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. Transplant Proc 20 Suppl 2 (1988) 207
78. Esa A.H., Paxman D.G., Noga S.J., and Hess A.D. Sensitivity of monocyte subpopulations to cyclosporine. Arachidonate metabolism and in vitro antigen presentation. Transplant Proc 20 Suppl 2 (1988) 80
79. Furue M., and Katz S.I. Cyclosporine A inhibits accessory cell and antigen-presenting cell functions of epidermal Langerhans cells. Transplant Proc 20 Suppl 2 (1988) 87
80. Noga S.J., Fischer A.C., Wagner J.E., et al. Cyclosporine A enhances the natural suppressor monocyte precursor population in the rat. Transplant Proc 20 Suppl 3 (1988) 1057
81. Heule F., Meinardi M.M., van Joost T., and Bos J.D. Low-dose cyclosporine effective in severe psoriasis: a double-blind study. Transplant Proc 20 Suppl 4 (1988) 32
82. Ponticelli C., and Rivolta E. Cyclosporine in nephrotic syndrome. Transplant Proc 20 Suppl 4 (1988) 253
83. Brodehl J., Hoyer P.F., Oemar B.S., et al. Cyclosporine treatment of nephrotic syndrome in children. Transplant Proc 20 Suppl 4 (1988) 269
84. Madhok R., and Capell H.A. Cyclosporine A in rheumatoid arthritis: results at 30 months. Transplant Proc 20 Suppl 4 (1988) 248
85. Brynskov J., Binder V., Riis P., et al. Cyclosporine in inflammatory bowel disease. Transplant Proc 20 Suppl 4 (1988) 309
86. Bach J.F. Cyclosporine in autoimmunity. Transplant Proc 20 Suppl 4 (1988) 379
87. Iwatsuki S., Esquivel C.O., Klintmalm G.B., et al. Nephrotoxicity of cyclosporine in liver transplantation. Transplant Proc 17 Suppl 1 (1985) 191
88. Grant D., Wall W., Duff J., et al. Adverse effects of cyclosporine therapy following liver transplantation. Transplant Proc 19 (1987) 3463
89. Gonwa T.A., Poplawski S.C., Husberg B.S., et al. Cyclosporine nephrotoxicity in orthotopic liver transplantation. Transplant Proc 20 Suppl 3 (1988) 401
90. Moran M., Tomlanovich S., and Myers B.D. Cyclosporine-induced chronic nephropathy in human recipients of cardiac allografts. Transplant Proc 17 Suppl 1 (1985) 185
91. Palestine A.G., Austin H.A., and Nussenblatt R.B. Cyclosporine-induced nephrotoxicity in patients with autoimmune uveitis. Transplant Proc 17 Suppl 1 (1985) 209
92. Stiller C.R., Keown P.A., Heinrichs D., et al. The effect of cyclosporine of renal function in newly diagnosed diabetes. Transplant Proc 17 Suppl 1 (1985) 202
93. Keown P.A., Stiller C.R., Wallace A.C., et al. Cyclosporine nephrotoxicity: exploration of the risk factors and prognosis of the renal injury. Transplant Proc 17 Suppl 1 (1985) 247
94. Taube D., Neild G., Hobby P., et al. A comparison of the clinical, histopathologic, cytologic, and biochemical features of renal transplant rejection, cyclosporine A nephrotoxicity, and stable renal function. Transplant Proc 17 Suppl 1 (1985) 179
95. Thiel G., Mihatsch M., Landmann J., et al. Is cyclosporine A-induced nephrotoxicity in recipients of renal allografts progressive?. Transplant Proc 17 Suppl 1 (1985) 169
96. Porter G.A., and Bennett W.M. Chronic cyclosporine-associated nephrotoxicity. Transplant Proc 18 Suppl 1 (1986) 204
97. Versluis D.J., Wenting G.J., Jeekel J., and Weimar W. Cyclosporine A-related proximal tubular dysfunction: impaired handling of uric acid. Transplant Proc 19 (1987) 4029
98. Tonnesen A.S., Hamner R.W., and Weinmann E.J. Cyclosporine and sodium and potassium excretion in the rat. Transplant Proc 15 Suppl 1 (1983) 2730
99. Vincent H.H., Wenting G.J., Versluis D.J., et al. Impaired fractional excretion of lithium: an early marker of cyclosporine-induced changes in renal hemodynamics. Transplant Proc 20 Suppl 3 (1988) 681
100. Morales J.M., Andres A., Alcazar J.M., et al. Usefulness of fractional excretion of sodium as index of cyclosporine nephrotoxicity in renal transplantation. Transplant Proc 20 Suppl 3 (1988) 691
101. Versluis D.J., Wenting G.J., Jeekel J., and Weimar W. The influence of cyclosporine A on proximal tubular function in renal allografts. Transplant Proc 20 Suppl 3 (1988) 686
102. Sommer B.G., Henry M.L., and Ferguson R.M. Cyclosporine-associated renal arteriopathy. Transplant Proc 18 Suppl 1 (1986) 151
103. Mihatsch M.J., Thiel G., and Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 20 Suppl 3 (1988) 759
104. Anaise D., Yland M.J., Atkins H., et al. Additive effects of cyclosporine and cold preservation upon the integrity of the renal cortical microcirculation. Transplant Proc 19 (1987) 3606
105. Schorn T., Frei U., Brackmann H., et al. Cyclosporine-associated posttransplant hypertension incidence and effect on renal transplant function. Transplant Proc 20 Suppl 3 (1988) 610
106. Dieperink H., Kemp E., and Starklint H. Cyclosporine A in high dosages induces renal intrstitial fibrosis in the rat. Transplant Proc 20 (1988) 525
107. Frei U., Margreiter R., Harms A., et al. Preoperative graft reperfusion with a calcium antagonist improves initial function: preliminary results of a prospective randomized trial in 110 kidney recipients. Transplant Proc 19 (1987) 3539
108. Foegh M.L., Alijani M., Helfrich G.B., et al. Urine thromboxane as an immunologic monitor in kidney transplant patients. Transplant Proc 16 (1984) 1603
109. Foegh M.L., Lim K., Douglas F., et al. Differential effects of CGS 13080, a thromboxane synthase inhibitor, in suppressing serum and urine immunoreactive thromboxane B2 in kidney transplant patients. Transplant Proc 20 Suppl 1 (1988) 424
110. Bennett W.M., Elzinga L., and Kelley V. Pathophysiology of cyclosporine nephrotoxicity: role of eicosanoids. Transplant Proc 20 Suppl 3 (1988) 628
111. Paller M.S. The prostaglandin E1 analog misoprostol reverses acute cyclosporine nephrotoxicity. Transplant Proc 20 Suppl 3 (1988) 634
112. Ballantyne C.M., Jones P.H., Payton-Ross C., et al. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc 19 Suppl 5 (1987) 60
113. Raine A.E., Carter R., Mann J.I., et al. Increased plasma LDL cholesterol after renal transplantation associated with cyclosporine immunosuppression. Transplant Proc 19 (1987) 1820
114. Oguma S., Okazaki H., Jimbo M., Iguchi A., Takahashi H., and Ishizaki M. Vascular rejection and arteriosclerosis. Transplant Proc 19 Suppl 5 (1987) 63
115. Muskett A., Burton N.A., Eichwald E.J., et al. The effect of antiplatelet drugs on graft atherosclerosis in rat heterotopic cardiac allografts. Transplant Proc 19 Suppl 5 (1987) 74
116. Gunnarsson R., Klintmalm G., Landgren G., et al. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. Transplant Proc 16 (1984) 709
117. Yale J.F., Chamelian M., Courchesne S., and Vigeant C. Peripheral insulin resistance and decreased insulin secretion after cyclosporine A treatment. Transplant Proc 20 Suppl 3 (1988) 985
118. Merion R.M., and Calne R.Y. Allograft renal vein thrombosis. Transplant Proc 17 (1985) 1746
119. Thiru S., Calne R.Y., and Nagington J. Lymphoma in renal allograft patients treated with cyclosporine-A as one of the immunosuppressive agents. Transplant Proc 13 (1981) 359
120. Penn I., and First M.R. Development and incidence of cancer following cyclosporine therapy. Transplant Proc 18 Suppl 1 (1986) 210
121. Lorber M.I., Van Buren C.T., Flechner S.M., et al. Hepatobiliary complications of cyclosporine therapy following renal transplantation. Transplant Proc 19 Pt 2 (1987) 1808
122. de Hemptinne B., Lamy M.E., Salizzoni M., et al. Successful treatment of cytomegalovirus disease with 9-(1,3-dihydroxy-2-propoxymethyl guanine). Transplant Proc 20 Suppl 1 (1988) 652
123. Shabtai M., Luft B., Waltzer W.C., et al. Massive cytomegalovirus pneumonia and myocarditis in a renal transplant recipient: successful treatment with DHPG. Transplant Proc 20 (1988) 562
124. Snydman D.R., Werner B.G., Tilney N.L., et al. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant Proc 20 Suppl 8 (1988) 24
125. Chapman J.R., and Morris P.J. Cyclosporine nephrotoxicity and the consequences of conversion to azathioprine. Transplant Proc 17 Suppl 1 (1985) 254
126. Flechner S.M., Lorber M., Van Buren C., et al. The case against conversion to azathioprine in cyclosporine-treated renal recipients. Transplant Proc 17 Suppl 1 (1985) 276
127. Sagalowsky A.I., Reisman M.E., Dawidson I., et al. Late cyclosporine conversion carries risk of irreversible rejection. Transplant Proc 20 Suppl 3 (1988) 157
128. Chapman J.R., and Morris P.J. Long-term effects of short-term cyclosporine. Transplant Proc 18 Suppl 1 (1986) 186
129. Hoitsma A.J., Tiggeler R.F., Wetzels J.F., et al. Cyclosporine treatment with conversion after three months is a safe treatment protocol in renal allograft recipients. Transplant Proc 20 Suppl 3 (1988) 161
130. Simmons R.L., Canafax D.M., Strand M., et al. Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prednisone. Transplant Proc 17 Suppl 1 (1985) 266
131. Lorber M.I., Flechner S.M., Van Buren C.T., et al. Cyclosporine, azathioprine, and prednisone as treatment for cyclosporine-induced nephrotoxicity in renal transplant recipients. Transplant Proc 17 Suppl 1 (1985) 282
132. Slapak M., Geoghegan T., Digard N., et al. The use of low-dose cyclosporine A in combination with azathioprine and steroids in renal transplantation. Transplant Proc 19 Suppl 2 (1987) 41
133. Fries D., Hiesse C., Santelli G., et al. Triple therapy with low-dose cyclosporine, azathioprine, and steroids: long-term results of a randomized study in cadaver donor renal transplantation. Transplant Proc 20 Suppl 3 (1988) 130
134. Takahara S., Fukunishi T., Kokado Y., et al. Combined immunosuppression with low-dose cyclosporine, mizoribine, and prednisolone. Transplant Proc 20 3 Suppl 3 (1988 Jun) 147-151
135. Kahan B.D., Ried M., and Newburger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15 (1983) 446
136. Newburger J., and Kahan B.D. Cyclosporine pharmacokinetics in man. Transplant Proc 15 Suppl 1 (1983) 2413
137. Keown P.A., Stiller C.R., Laupacis A.L., et al. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 14 (1982) 659
138. Holt D.W., Marsden J.T., and Johnston A. Measurement of cyclosporine: methodological problems. Transplant Proc 18 Suppl 5 (1986) 101
139. Frey B.M., Appenzeller M., Gautschi K., et al. Measurements of cyclosporine A by RIA in different centers are not comparable. Transplant Proc 19 Pt 2 (1987) 1713
140. Gibbons S., Grevel J., Reynolds K., et al. Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients. Transplant Proc 20 Suppl 2 (1988) 339
141. Kahan B.D., Wideman C.A., Reid M., et al. The value of serial serum trough cyclosporine levels in human renal transplantation. Transplant Proc 16 (1984) 1195
142. Rosano T.G., Pell M.A., Freed B.M., et al. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplant Proc 20 Suppl 2 (1988) 330
143. Cockburn I. Cyclosporine A: a clinical evaluation of drug interactions. Transplant Proc 18 Suppl 5 (1986) 50
144. Quesniaux V., Schreier M.H., and Van Regenmortel M.H. The potential of monoclonal antibodies for cyclosporine monitoring. Transplant Proc 19 (1987) 1715
145. Kahan B.D., Kramer W.G., Wideman C.A., et al. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. Transplant Proc 18 Suppl 5 (1986) 115
146. Walker K.B., House A.K., Maley M.A., and Potter J.M. Prednisolone half-life and T lymphocytes in renal allograft recipients. Transplant Proc 17 (1985) 1679
147. Ochiai T., Nakajima K., Nagata M., et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 9 (1987) 1284
148. Starzl T.E., Makowka L., and Todo S. First International Workshop on FK-506. A potential breakthrough in immunosuppression. Proceedings. Transplant Proc 19 Suppl 6 (1987) 1
149. Goto T., Kino T., Hatanaka H., et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 19 Suppl 6 (1987) 4
150. Kino T., Inamura N., Sakai F., et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 19 Suppl 6 (1987) 36
151. Zeevi A., Duquesnoy R., Eiras G., et al. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc 19 Suppl 6 (1987) 40
152. Calne R., Collier D.S., and Thiru S. Observations about FK-506 in primates. Transplant Proc 19 Suppl 6 (1987) 63
153. Collier D.S., Calne R., Thiru S., et al. FK-506 in experimental renal allografts. Transplant Proc 19 (1987) 3975
154. Todo S., Demetris A.J., Ueda Y., et al. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc 19 Suppl 6 (1987) 57
155. Cochrum K., Hanes D., Potter D., et al. Improved graft survival with donor-specific transfusion pretreatment. Transplant Proc 13 Pt 1 (1981) 190
156. Opelz G., Terasaki P.I., Graver B., et al. Correlation between number of pretransplant blood transfusions and kidney graft survival. Transplant Proc 11 (1979) 145
157. Hunsicker L.G., Oei L.S., Freeman R.M., et al. Effect of blood transfusions on cadaver renal allograft survival. Transplant Proc 11 (1979) 156
158. Fehrman I., Groth C.G., Lundgren G., et al. Pretransplant dialysis and blood transfusion-correlation with cadaveric kidney graft survival. Transplant Proc 11 (1979) 152
159. Bore P.J., Sells R.A., Jamieson V., and Burrows K. Transfusion-induced renal allograft protection. Transplant Proc 11 (1979) 148
160. Sengar D.P., Rashid A., and Jindal S.L. Effect of blood transfusions on renal allograft survival. Transplant Proc 11 (1979) 179
161. Williams K.A., Ting A., Cullen P.R., and Morris P.J. Transfusions: their influence on human renal graft survival. Transplant Proc 11 (1979) 175
162. Solheim B.G., Flatmark A., Halvorsen S., et al. Influence of HLA-A, B, C, and D matching and pretransplant blood transfusions on kidney graft survival. Transplant Proc 11 (1979) 748
163. Spees E.K., Vaughn W.K., Niblack G., et al. The effects of blood transfusion on cadaver renal transplantation: a prospective study of the Southeastern Organ Procurement Foundation 1977-1980. Transplant Proc 13 Pt 1 (1981) 155
164. Persijn G.G., van Leeuwen A., Parlevliet J., et al. Two major factors influencing kidney graft survival in Eurotransplant: HLA-DR matching and blood transfusion(s). Transplant Proc 13 (1981) 150
165. Burrows L., Schanzer H., Miller C., et al. Effects of repeated, small aliquot, same donor transfusions of HL-A defined blood on prospective recipients. Transplant Proc 14 2 (1982 Jun) 272-275
166. Fuller T.C., Burroughs J.C., Delmonico F.L., et al. Influence of frozen blood transfusions on renal allograft survival. Transplant Proc 14 (1982) 293
167. Takahashi H., Iwaki Y., Terasaki P.I., et al. Deliberate buffy-coat transfusions and the risk of antibody formation. Transplant Proc 14 (1982) 349
168. [No authors listed]. First International Symposium on the Role of Blood Transfusion in Transplantation. February 1-3, 1982, Los Angeles, California. Proceedings. Transplant Proc 14 (1982) 247
169. Jeannet M., Néri-Legendre C., Descoeudres C., and Leski M. Does blood transfusion induce a nonspecific suppression of cell-mediated immunity?. Transplant Proc 14 (1982) 325
170. Fagnilli L., and Singal D.P. Blood transfusions may induce anti-T cell receptor antibodies in renal patients. Transplant Proc 14 (1982) 319
171. Guttmann R.D., McIntyre C., Poulsen R.S., et al. Effect of blood transfusion on the development of cytotoxic antibody and immunoregulatory lymphocyte subsets enumerated by monoclonal antibodies and FACS analysis. Transplant Proc 14 (1982) 344
172. Austyn J.M., Peugh W.N., Hankins D., et al. Dendritic cells in the blood transfusion effect. Transplant Proc 19 (1987) 1434
173. Heineman E., Bouwman E., Marquet R.L., et al. Modified graft rejection by transfusion of the donor: a role for dendritic cells. Transplant Proc 19 (1987) 1470
174. Takiff H., Novak M., Yin L., et al. Examination of the clonal deletion hypothesis following transfusions in rat cardiac transplants. Transplant Proc 19 (1987) 1452
175. Ford C.D., Warnick C.T., Sheets S., et al. Blood transfusions lower natural killer cell activity. Transplant Proc 19 (1987) 1456
176. Heyd T.J., Perez R.V., Trocki O., and Alexander J.W. Manipulations of arachidonic acid metabolism using a 5-lipoxygenase inhibitor in transfusion-induced immunosuppression. Transplant Proc 20 (1988) 1186
177. Cardella C.J., Falk J.A., Peters P., et al. Do repeated blood transfusions prevent successful transplantation in highly sensitized potential transplant recipients?. Transplant Proc 14 (1982) 359
178. Etheredge E.E., Bettonville P., Sicard G.A., et al. Serologic response to donor-specific blood transfusions under azathioprine immunosuppression. Transplant Proc 19 (1987) 746
179. Stratta R.J., Burlingham W.J., Pirsch J.D., et al. Risk factors for rejection in a donor-specific transfusion plus azathioprine protocol. Transplant Proc 20 (1988) 1092
180. Melzer J.S., Husing R.M., Feduska N.J., et al. Has cyclosporine really relegated pretransplant blood transfusions to therapeutic obsolescence?. Transplant Proc 19 (1987) 1971
181. Brynger H., Persson H., Flatmark A., et al. No effect of blood transfusions or HLA matching on renal graft success rate in recipients treated with cyclosporine-prednisolone or cyclosporine-azathioprine-prednisolone: the Scandinavian experience. Transplant Proc 20 Suppl 3 (1988) 261
182. Kerman R.H., Van Buren C.T., Lewis R.M., and Kahan B.D. Impact of blood transfusions and HLA on cyclosporine-treated renal transplant recipients. Transplant Proc 20 Suppl 3 (1988) 264
183. Opelz G. Improved kidney graft survival in nontransfused recipients. Transplant Proc 19 (1987) 149
184. Diethelm A.G., Blackstone E., Whelchel J.D., et al. The adjunctive value of equine antithymocyte membrane globulin in a randomized study of patients undergoing cadaveric renal transplantation. Transplant Proc 11 (1979) 27
185. Kerman R.H., Floyd M., Van Buren C.T., and Kahan B.D. Prolonged allograft survival of strong pretransplant immune responders treated with ATG. Transplant Proc 13 (1981) 332
186. Rodt H., Kolb H.J., Netzel B., et al. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc 13 (1981) 257
187. Light J.A., Alijani M.R., Biggers J.A., et al. Antilymphocyte globulin (ALG) reverses "irreversible" allograft rejection. Transplant Proc 13 (1981) 475
188. Adams M.B., Kauffman Jr. H.M., Hussey C.V., et al. Plasmapheresis in the treatment of refractory renal allograft rejection. Transplant Proc 13 (1981) 491
189. Franco A., Anaya F., Niembro E., et al. Plasma exchange in the treatment of vascular rejection. Relationship between histological changes and therapeutic response. Transplant Proc 19 (1987) 3661
190. Kung P.C., Talle M.A., DeMaria M.E., et al. Strategies for generating monoclonal antibodies defining human t-lymphocyte differentiation antigens. Transplant Proc 12 Suppl 1 (1980) 141
191. Cosimi A.B., Colvin R.B., Burton R.C., et al. Immunologic monitoring with monoclonal antibodies to human T-cell subsets. Transplant Proc 13 (1981) 1589
192. Chatenoud L., Kreis H., Jungers P., and Bach K.F. The effect of immunosuppressive agents on T- cell subsets, as evaluated by use of monoclonal anti-T-cell antibodies. Transplant Proc 13 (1981) 1651
193. Cosimi A.B. Clinical development of Orthoclone OKT3. Transplant Proc 19 Suppl 1 (1987) 7
194. Goldstein G. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant Proc 19 Suppl 1 (1987) 1
195. Cosimi A.B., Cho S.I., Delmonico F.L., et al. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplant Proc 19 (1987) 2431
196. Fung J.J., Markus B.H., Gordon R.D., et al. Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc 19 Suppl 1 (1987) 37
197. Monaco A., Goldstein G., and Barnes L. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens. Transplant Proc 19 Suppl 1 (1987) 28
198. Thistlethwaite Jr. J.R., Haag B.W., Gaber A.O., et al. Stuart FP. The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine. Transplant Proc 19 1 Pt 3 (1987 Feb) 1901-1904
199. Lord R.H., Hancock W.W., Colby A.J., et al. Effects of anti-IL 2 receptor monoclonal antibody and cyclosporine on IL 2 receptor-positive cells infiltrating cardiac allografts in the rat. Transplant Proc 19 (1987) 354
200. Shapiro M.E., Kirkman R.L., Reed M.H., et al. Monoclonal anti-IL-2 receptor antibody in primate renal transplantation. Transplant Proc 19 (1987) 594
201. Soulillou J.P., Le Mauff B., Cantarovich D., et al. Use of a monoclonal antibody directed against interleukin 2 receptor in recipients of kidney allografts. Transplant Proc 20 Suppl 6 (1988) 84
202. Friend P.J., Tighe H., Lim S., et al. The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon. Transplant Proc 19 (1987) 4317
203. Riggio R.R., Cheigh J.S., Stubenbord W.T., et al. Immunosuppressive properties of placental-source gamma globulin: results of a 5-year clinical investigative study in a cadaver kidney transplant program. Transplant Proc 11 (1979) 1424
204. Tax W.J., van de Heijden H.M., Willems H.W., et al. Immunosuppression with monoclonal anti-T3 antibody (WT32) in renal transplantation. Transplant Proc 19 (1987) 1905
205. Milford E.L., Carpenter C.B., Kirkman R.L., et al. Anti-T12 monoclonal antibody therapy of acute renal allograft rejection. Transplant Proc 19 (1987) 1910
206. Nashan B., Wonigeit K., Schwinzer R., et al. Fine specificity of a panel of antibodies against the TCR/CD3 complex. Transplant Proc 19 (1987) 4270
207. Lazarovits A.I., and Karsh J. A monoclonal antibody, 7G5 (CD7), induces modulation of Tp40 and inhibits proliferation in the allogeneic and autologous mixed lymphocyte reactions. Transplant Proc 20 (1988) 1253
208. Nemoto K., Ito J., Hayashi M., et al. Effects of spergualin and 15-deoxyspergualin on the development of graft-versus-host disease in mice. Transplant Proc 19 (1987) 3520
209. Falk W., Ulrichs K., and Müller-Ruchholtz W. 15-Deoxyspergualin (a new guanidine-like drug) blocks T lymphocyte proliferation. Transplant Proc 19 (1987) 4239
210. Schubert G., Stoffregen C., Timmermann W., et al. Comparison of the new immunosuppressive agent 15-deoxyspergualin and cyclosporine A after highly allogeneic pancreas transplantation. Transplant Proc 19 (1987) 3978
211. Suzuki S., Kanashiro M., and Amemiya H. Immunosuppressive effect of a new drug, 15-deoxyspergualin, in heterotopic rat heart transplantation: in vivo energy metabolic studies by 31P-NMR spectroscopy. Transplant Proc 19 (1987) 3982
212. Engemann R., Gassel H.J., Lafrenz E., et al. Transplantation tolerance after short-term administration of 15-deoxyspergualin in orthotopic rat liver transplantation. Transplant Proc 19 (1987) 4241
213. Walter P., Dickneite G., Feifel G., and Thies J. Deoxyspergualin induces tolerance in allogeneic kidney transplantation. Transplant Proc 19 (1987) 3980
214. Strom T.B., and Carpenter C.B. Cyclic nucleotides in immunosuppression-neuroendocrine pharmacologic manipulation and in vivo immunoregulation of immunity acting via second messenger systems. Transplant Proc 12 (1980) 304
215. Miller J.J. The imidazoles as immunosuppressive agents. Transplant Proc 12 (1980) 300
216. Kagawa K., Kasahara K., Sakurai Y., et al. Prolongation of rat cardiac allograft survival with arachidonic acid metabolism inhibitor. Transplant Proc 19 (1987) 1308
217. Montgomery D.W., Celniker A., and Zukoski C.F. Didemnin B: an immunosuppressive cyclic peptide that stimulates murine antibody responses in vivo and in vitro. Transplant Proc 19 (1987) 1295
218. Teraoka S., Takahashi K., Toma H., et al. Application of prostacyclin analogue and thromboxane synthetase inhibitor to chronic vascular rejection after kidney transplantation. Transplant Proc 19 (1987) 3664
219. Wahlberg J., Andersson T., Busch C., et al. The biopty biopsy technique: a major advance in the monitoring of renal transplant recipients. Transplant Proc 20 (1988) 419
220. Eklund B., Edgren J., Laasonen L., and Ahonen J. Percutaneous nephrostomy: a therapeutic procedure for the management of urinary leakage and obstruction in renal transplantation. Transplant Proc 16 (1984) 1304
221. Perner F., Járay J., Alföldy F., et al. Experiences with ureteroureteral anastomosis in renal transplant: early complications and late results. Transplant Proc 16 (1984) 1335
222. Waltzer W.C., Frischer Z., Anaise D., et al. Restoration of urinary tract continuity after necrosis of the pelvis and ureter in a transplanted kidney: the Boari flap. Transplant Proc 16 (1984) 1367
223. Baumgartner D., Keusch G., Retsch M., and Largiadèr F. Correction of renal transplant artery stenosis: early and long-term results. Transplant Proc 16 (1984) 1308
224. Groth C.G., Lundgren G., Gunnarsson R., et al. Segmental pancreatic transplantation with special reference to the use of ileal exocrine diversion and to the hemodynamic of the graft. Transplant Proc 12 Suppl 2 (1980) 62
225. Corry R.J., and West J.C. Duct drainage through a long polyethylene catheter in Roux-en-Y limb. Transplant Proc 12 Suppl 2 (1980) 93
226. Tellis V.A., Veith F.J., and Gliedman M.L. Ten-year experience with human pancreatic transplantation. Transplant Proc 12 Suppl 2 (1980) 78
227. McAnulty J.F., Southard J.H., and Belzer F.O. Improved maintenance of adenosine triphosphate in five-day perfused kidneys with adenine and ribose. Transplant Proc 19 (1987) 1376
228. Maessen J.F., Van der Vusse G.J., Vork M., and Kootstra G. Inability to maintain adenine nucleotide levels by cold storage in ischemically damaged and control kidneys. Transplant Proc 19 (1987) 4112
229. Ploeg R.J., Goossens D., Vreugdenhil P., et al. Successful 72-hour cold storage kidney preservation with UW solution. Transplant Proc 20 Suppl 1 (1988) 935
230. Novitzky D., Cooper D.K., Morrell D., and Isaacs S. Brain death, triiodothyronine depletion, and inhibition of oxidative phosphorylation: relevance to management of organ donors. Transplant Proc 19 (1987) 4110
231. Kneteman N.M., Alderson D., and Scharp D.W. The isolation and purification of human pancreatic islets. Transplant Proc 19 (1987) 3469
232. Land W. The world experience in clinical pancreas transplantation. Proceedings of the Second International Workshop on Clinical Pancreatic Transplantation. December 7-10, 1986, Munich/Spitzingsee, FR Germany. Transplant Proc 19 Suppl 4 (1986) 1
233. Thorsby E. Structure and function of HLA molecules. Transplant Proc 19 (1987) 29
234. Thorsby E. The human major histocompatibility complex HLA: some recent developments. Transplant Proc 11 (1979) 616
235. Balner H. Are D and DR antigens identical?. A review of available data for man and the rhesus monkey. Transplant Proc 11 (1979) 657
236. White D., and Lunney J. Transplantation in pigs. Transplant Proc 11 (1979) 1170
237. Neauport-Sautes C., Joskowicz M., and Demant P. Further evidence for two separate loci (H-2D and H-2L) in the D region of the H-2 complex. Transplant Proc 11 (1979) 1322
238. Gill III T.J. Major histocompatibility complex of the rat. Transplant Proc 11 (1979) 1174
239. Götze D. An immunogenetic analysis of the MHC of the rat-AgB(RT1). I. Serologic data. Transplant Proc 11 (1979) 1337
240. Wonigeit K. Definition of lymphocyte antigens in rats: RT-Ly-1, RT-Ly-2, and a new MHC-linked antigen system. Transplant Proc 11 (1979) 1334
241. Günther E., and Stark O. Overview. The major histocompatibility system of the rat. Transplant Proc 11 (1979) 1550
242. Shimoyama H., Horimi T., Inoko H., et al. A new approach to tissue typing in kidney transplantation: DNA typing. Transplant Proc 19 (1987) 836
243. van R.J.J. Prospective HLA typing is helpful in cadaveric renal transplantation. Transplant Proc 19 (1987) 139
244. Hardy M.A. Prospective HLA typing is helpful in cadaveric renal transplantation. Transplant Proc 19 (1987) 144
245. Mann D.L., Kaufman J., Orr H., et al. Serologic and structural studies of DR-related antigens. Transplant Proc 11 (1979) 668
246. Ettenger R.B., Robinson B.J., Uittenbogaart C.H., et al. Antibodies to donor B lymphocytes and autoantibodies in renal transplantation. Transplant Proc 11 (1979) 401
247. Ting A., and Morris P.J. The influence of HLA-DR matching on renal transplant outcome. Transplant Proc 11 (1979) 1295
248. Hardy M., Suciu-Foca N., McKiernan T., et al. The development and specificity of anti-B-cell antibodies during humoral rejection of kidney allografts. Transplant Proc 11 (1979) 389
249. Fotino M., Gibofsky A., Cheigh J.S., et al. Adverse presensitization: detection by utilization of B lymphoblastoid cell panels. Transplant Proc 11 (1979) 1263
250. van Hoff J.P., van Hooff-Eijkenboom Y.E., Kalff M.W., et al. Kidney graft survival, clinical course, and HLA-A, B, and D matching in 208 patients transplanted in one center. Transplant Proc 11 (1979) 1291
251. Soulillou J.P., de Mouzon A., Peyrat M.A., and Guenel J. Role of anti-donor B lymphocyte antibodies in definitive allograft rejection. Transplant Proc 11 (1979) 770
252. Bonneville M., Moreau J.F., Blokland E., et al. Products of HLA class I and class II (B, C, DP, DQ, DR) genes all contribute to induction of recipient anti-donor responses in rejected kidneys. Transplant Proc 20 (1988) 193
253. Mohanakumar T., Siegel W., Mendez G., et al. B-lymphocyte and kidney cell cross-reactive antibodies eluted from rejected human renal allografts. Transplant Proc 11 4 (1979 Dec) 1896-1898
254. d'Apice A.J., and Tait B.D. The positive B-cell cross-match: a marker of active enhancement?. Transplant Proc 11 (1979) 954
255. Thistlethwaite Jr. J.R., Buckingham M., Stuart J.K., et al. T cell immunofluorescence flow cytometry cross-match results in cadaver donor renal transplantation. Transplant Proc 19 (1987) 722
256. Rodey G., Bollig B., Oldfather J., et al. Extra reactivities detected in flow-cytometry-positive, CDC-negative crossmatches are definable HLA specificities. Transplant Proc 19 (1987) 778
257. Opelz G. Kidney transplantation in sensitized patients. Transplant Proc 19 (1987) 3737
258. Bradley B.A., and Gore S.M. Council of Europe study of high sensitization in renal transplantation. Transplant Proc 19 (1987) 3742
259. Busson M., Bouteiller A.M., Prevost P., et al. Can the profile of preformed HLA antibodies in highly sensitized recipients influence the outcome of their kidney transplants?. Transplant Proc 19 (1987) 3746
260. Fauchald P., Leivestad T., Bratlie A., et al. Plasma exchange and immunosuppressive therapy before renal transplantation in allosensitized patients. Transplant Proc 19 (1987) 3748
261. Palmer A., Taube D., Welsh K., et al. Extracorporeal immunoadsorption of anti-HLA antibodies: preliminary clinical experience. Transplant Proc 19 (1987) 3750
262. Zinkernagel R.M. Association of disease susceptibility to major histocompatibility antigens. Transplant Proc 11 (1979) 624
263. Festenstein H., and Nyulassy S. Workshop on HLA and disease. Transplant Proc 11 (1979) 1183
264. Paul L.C., van Es L.A., Kalff M.W., and de Graeff J. Intrarenal distribution of endothelial antigens recognized by antibodies from renal allograft recipients. Transplant Proc 11 (1979) 427
265. Paul L.C., and Carpenter C.B. Antibodies against renal endothelial alloantigens. Transplant Proc 12 Suppl 1 (1980) 43
266. Cerilli J., and Brasile L. Endothelial cell alloantigens. Transplant Proc 12 Suppl 1 (1980) 37
267. Johny M., Pazderka F., Kovithavongs T., et al. Monocyte-specific antigens-detection by the antibody-dependent cellular cytotoxicity (ADCC) method. Transplant Proc 11 (1979) 1970
268. Stastny P. Endothelial-monocyte antigens. Transplant Proc 12 Suppl 1 (1980) 32
269. Metzgar R.S. Pancreas-specific alloantigens. Transplant Proc 12 Suppl 1 (1980) 123
270. Lalezari P. Organ-specific and systemic alloantigens: Interrelationships and biologic implications. Transplant Proc 12 Suppl 1 (1980) 12
271. Wilson C.B. Individual and strain differences in renal basement membrane antigens. Transplant Proc 12 Suppl 1 (1980) 69
272. Claas F.H., van Rood J.J., Warren R.P., et al. The detection of non-HLA antibodies and their possible role in bone marrow graft rejection. Transplant Proc 11 (1979) 423
273. Gunther E. The response to the H-Y antigen which is restricted by Class I MHC antigens. Transplant Proc 17 (1985) 1849
274. Halle-Pannenko O., Pritchard L.I., Motta R., et al. Lethal graft-versus-host reaction to minor histocompatibility antigens is decreased by donor immunization against H-2 and varies as a function of the H-2 haplotype. Transplant Proc 11 (1979) 652
275. Brent L. Immunologic manipulation: specific mechanisms. Transplant Proc 11 (1979) 839
276. Gratwohl A., Baldomero H., Nissen C., and Speck B. Induction of tolerance by combined allogeneic and autologous bone marrow transplantation. Transplant Proc 19 (1987) 4256
277. Hewitt C.W., Black K.S., Henson L.E., et al. Lymphocyte chimerism in a full allogeneic composite tissue (rat-limb) allograft model prolonged with cyclosporine. Transplant Proc 20 Suppl 2 (1988) 272
278. Monaco A.P., Wood M.L., Maki T., and Gozzo J.J. Post transplantation donor-specific bone marrow transfusion in polyclonal antilymphocyte serum-treated recipients: the optimal cellular antigen for induction of unresponsiveness to organ allografts. Transplant Proc 20 (1988) 1207
279. Auchincloss Jr. H., Ghobrial R.R., Shea S., et al. Failure to induce chimerism or tolerance in mice with monoclonal anti-T cell antibodies plus allogeneic bone marrow infusion. Transplant Proc 20 (1988) 1190
280. Holan V., Hasek M., Hilgert I., et al. Regulatory mechanisms in transplantation tolerance induced in different genetic combinations of mice. Transplant Proc 13 (1981) 608
281. Satoh P., Elberg A., Davis J., et al. Effects of different ATG (ATGAM) regimens on levels of rosette-forming cells (RFC), serum horse IgG (HoI), and anti-horse antibodies in kidney transplant patients. Transplant Proc 11 (1979) 1427
282. McAlack R.F., Stern S., Beizer R., et al. Immunologic monitoring parameters in ALG- versus non-ALG-treated renal transplant patients. Transplant Proc 11 (1979) 1431
283. Vincent C., Revillard J.P., Pellet H., and Traeger J. beta2-microglobulin in monitoring renal transplant function. Transplant Proc 11 (1979) 438
284. Schweizer R.T., Moore R., Bartus S.A., et al. Beta 2-microglobulin monitoring after renal transplantation. Transplant Proc 13 (1981) 1620
285. Stiller C.R., and Sinclair N.R. Monitoring of rejection. Transplant Proc 11 (1979) 343
286. Dossetor J.B., Kovithavongs T., Schlaut J., et al. Donor-specific monitoring of transplant patients. Transplant Proc 11 (1979) 1235
287. Snider M.E., and Steinmuller D. Nonspecific tissue destruction as a consequence of cytotoxic T lymphocyte interaction with antigen-specific target cells. Transplant Proc 19 (1987) 421
288. Berke G., and Rosen D. Are lytic granules and perforin a involved in lysis induced by in vivo-primed peritoneal exudate cytolytic T lymphocytes?. Transplant Proc 19 (1987) 412
289. van Rood J.J., Persijn G.G., van Leeuwen A., et al. A new strategy to improve kidney graft survival: the induction of CML nonresponsiveness. Transplant Proc 11 (1979) 736
290. Wood P.J., Strome P., and Streilein J.W. Clonal frequency of alloreactive cells in mice tolerant of H-2. Transplant Proc 17 (1985) 1137
291. Stiller C. Second International Symposium on Immunologic Monitoring of the Transplant Recipient. Transplant Proc 13 (1981) 1519
292. Keown P.A., Stiller C.R., Bloch M., et al. Pretransplant immunologic reactivity to donor lymphocytes-lack of correlation with posttransplant events. Transplant Proc 13 (1981) 1563
293. Hamilton D.N., Briggs J.D., Watson M.A., et al. Predictive value of measurement of cell-mediated immunity on outcome of renal transplantation. Transplant Proc 13 (1981) 1561
294. Steinmuller D. Passenger leukocytes and the immunogenicity of skin allografts: a critical reevaluation. Transplant Proc 13 (1981) 1094
295. Hart D.N., and Fabre J.W. Localization of MHC antigens in long surviving rat renal allografts: probable implication of passenger leukocytes in graft adaptation. Transplant Proc 13 (1981) 95
296. Gassel H.J., Engemann R., Thiede A., et al. Replacement of donor Kupffer cells by recipient cells after orthotopic rat liver transplantation. Transplant Proc 19 (1987) 351
297. Hoffman R.A., AScher N.L., and Simmons R.L. Migratory behavior of lymphocytes during allograft rejection. Transplant Proc 13 (1981) 1102
298. Ascher N.L. Effector mechanisms in allograft rejection. Transplant Proc 19 (1987) 57
299. Manca F., Ferry B., Jaakkola M., et al. T helper cells infiltrating kidney allografts: frequency and functional characterization. Transplant Proc 19 (1987) 386
300. Orosz C.G., Adams P.W., and Ferguson R.M. Limiting dilution analysis of human alloantigen-reactive helper T lymphocytes. Transplant Proc 19 (1987) 328
301. Zanker B., Kabelitz D., Franz H.E., and Wagner H. Limiting dilution analysis: a new approach to study allograft acceptance. Transplant Proc 19 (1987) 1559
302. Mottram P.L., Wheelahan J., Mirisklavos A., et al. Prolongation of murine cardiac allografts following treatment of graft recipients with monoclonal anti-L3T4 and Ly-2 antibodies. Transplant Proc 19 (1987) 582
303. Cranston D., Wood K.J., Carter N.P., and Morris P.J. Suppression of allograft rejection in the rat by pretreatment with cells of the T-helper, but not T-cytotoxic suppressor phenotype. Transplant Proc 19 (1987) 505
304. Padberg W.M., Kupiec-Weglinski J.W., Lord R.H., et al. W3/25+ T cells mediate specific unresponsiveness in enhanced allograft recipients. Transplant Proc 19 (1987) 493
305. Cosimi A.B., Burton R.C., Kung P.C., et al. Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses. Transplant Proc 13 (1981) 499
306. Binz H., and Wigzell H. Antiidiotype antibodies: induction of specific transplantation tolerance in adult animals. Transplant Proc 11 (1979) 914
307. Suciu-Foca N., Rohowsky C., Kung P., et al. MHC-specific idiotypes on alloactivated human T cells in vivo and in vitro studies. Transplant Proc 1 (1983) 784
308. Reed E., Hardy M., Lattes C., et al. Antidiotypic andibodies and their relevance to transplantation. Transplant Proc 17 (1985) 735
309. Thomas J.M., Thomas F.T., Hoffman S., et al. Donor-specific CML hyporesponsiveness after successful renal transplantation: studies on the mechanism. Transplant Proc 11 (1979) 1258
310. Feighery C.F., and Stastny P. Specific inhibition of T-cell-mediated cytolosis by alloantiserum against HLA-D-related (DR) antigens. Transplant Proc 11 (1979) 708
311. Hutchinson I.V., Brent H., and Brent L. Enhancement of tumor, skin, and kidney allografts using TNP-conjugated alloantigens and anti-TNP antibody. Transplant Proc 15 (1983) 819
312. Miller J., Clark C., and Flaa C. In vitro generation of suppressor cells in human mixed leukocyte culture: a potential treatment modality in organ transplantation. Transplant Proc 11 (1979) 899
313. Slavin S., Zan-Bar I., and Strober S. Generation of protein-specific and alloantigen-specific suppressor cells following total lymphoid irradiation in mice. Transplant Proc 11 (1979) 891
314. Tutschka P.J., Santos G.W., and Beschorner W. Role of suppressor cells in transplantation tolerance. Transplant Proc 11 (1979) 882
315. Bernstein A., Sopori M.L., Gose J.E., and Sondel P.M. Modulation of immune response by alloactivated suppressor T cells. Transplant Proc 11 (1979) 997
316. Goeken N.E., and Thompson J.S. Kinetic characteristics of human suppressor cells. Transplant Proc 11 (1979) 1823
317. Charpentier B., Lang P., Martin B., and Fries D. Evidence for a suppressor cell system in human kidney allograft tolerance. Transplant Proc 13 (1981) 90
318. Kaneda I., Miura K., Sasaki T., et al. Macrophage as a suppressor cell or a helper cell in human renal transplant patients. Transplant Proc 13 (1981) 678
319. Rammensee H.G., Fink P.J., and Bevan M.J. The veto concept: An economic system for maintaining self-tolerance of cytotoxic T lymphocytes. Transplant Proc 17 (1985) 689
320. Evans C.D. A human rights perspective on donor legislation. Transplant Proc 17 Suppl 4 (1985) 69
321. Evans R.W. The socioeconomics of organ transplantation. Transplant Proc 17 Suppl 4 (1985) 129
322. Keown P.A., Arbus G.S., Bennett R.C., et al. Organ retrieval and distribution. Transplant Proc 17 Suppl 3 (1985) 71
323. Sharpe G. Commerce in tissue and organs. Transplant Proc 17 Suppl 4 (1985) 33
324. Corlett S. Public attitudes toward human organ donation. Transplant Proc 17 Suppl 3 (1985) 103
325. Stiller C.R., Lindberg M.C., Rimstead D., et al. Living related donation. Transplant Proc 17 Suppl 3 (1985) 85
326. Caplan A.L. Requests, gifts, and obligations: the ethics of organ procurement. Transplant Proc 18 Suppl 2 (1986) 49
327. Veatch R.M. The ethics of xenografts. Transplant Proc 18 Suppl 2 (1986) 93
328. Rapaport F.T. The case for a living emotionally related international kidney donor exchange registry. Transplant Proc 18 Suppl 2 (1986) 5
329. Moore F.D. Three ethical revolutions: ancient assumptions remodeled under pressure of transplantation. Transplant Proc 20 Suppl 1 (1988) 1061